Creative Medical Technology Holdings, Inc. (CELZ) Income Statement
CELZ 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCELZ revenue and net income
Where CELZ's revenue goes
2025Each bar shows an amount and its share of revenue. CELZ kept −99,916.8% of revenue as net income.
CELZ profit margins
CELZ growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −45.5% | −59.2% | −48.4% | — |
| Gross profit | −42.3% | −60.1% | −49.3% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CELZ quarterly EPS vs estimates
Creative Medical Technology beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 6, 2026 (estimate $-0.24).
CELZ income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6,000 | $11,000 | $9,000 | $88,600 | $87,754 | $164,500 | $165,500 | $124,400 | $4,800 | $0 |
| Cost of revenue | $2,194 | $4,400 | $3,600 | $28,491 | $47,949 | $50,596 | $45,499 | $70,375 | $8,000 | $766,072 |
| Gross profit | $3,806 | $6,600 | $5,400 | $60,109 | $39,805 | $113,904 | $120,001 | $54,025 | −$3,200 | −$766,072 |
| Research & development | $2.3M | $2.4M | $2.0M | $6.3M | $109,180 | $0 | $0 | $96,621 | $260,085 | $85,334 |
| Sales, general & admin | $3.8M | $3.2M | $3.1M | $3.9M | $3.0M | $1.2M | $1.2M | $1.1M | $898,526 | $664,984 |
| Total operating expenses | $6.1M | $5.8M | $5.6M | $10.3M | $3.2M | $1.2M | $1.3M | $1.2M | $1.2M | $759,674 |
| Operating income | −$6.1M | −$5.7M | −$5.6M | −$10.2M | −$3.1M | −$1.1M | −$1.1M | −$1.1M | −$1.2M | −$766,072 |
| Interest income | $147,806 | $250,380 | $302,538 | $100,328 | $0 | — | — | — | — | — |
| Interest expense | — | — | — | $100,328 | $4.3M | $1.2M | $1.9M | $1.4M | $377,587 | $6,398 |
| Income before taxes | −$6.0M | −$5.5M | −$5.3M | −$10.1M | $19.2M | −$36.3M | −$8.5M | −$13.7M | −$2.7M | −$766,072 |
| Income taxes | — | — | −$4 | −$100,328 | $4.3M | $1.2M | $1.9M | −$11.2M | $377,587 | $12,796 |
| Net income | −$6.0M | −$5.5M | −$5.3M | −$10.1M | $19.2M | −$36.3M | −$8.5M | −$13.7M | −$2.7M | −$766,072 |
| EBITDA | −$6.0M | −$5.4M | −$5.2M | −$10.1M | $23.6M | −$35.0M | −$6.6M | −$1.1M | −$1.2M | −$750,318 |
| EPS (diluted) | −$2.59 | −$3.71 | −$3.69 | −$4.57 | $5.02 | −$37.08 | −$269.64 | $120.75 | −$9.43 | −$1.28 |
| Gross margin | 63.4% | 60.0% | 60.0% | 67.8% | 45.4% | 69.2% | 72.5% | 43.4% | −66.7% | — |
| Operating margin | −102,380.2% | −52,216.9% | −62,445.9% | −11,562.5% | −3,562.2% | −677.7% | −682.9% | −895.7% | −24,537.6% | — |
| Net margin | −99,916.8% | −49,940.7% | −58,739.7% | −11,449.3% | 21,892.8% | −22,082.2% | −5,126.1% | −10,977.2% | −55,398.1% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3,000 | $0 | $0 | $3,000 | $3,000 | $0 | $8,000 | $3,000 | $3,000 | $6,000 |
| Cost of revenue | $22,918 | $28,855 | $994 | $31,059 | $30,742 | $1,200 | $1,200 | $29,271 | $3,200 | $29,271 | $26,721 | $2,400 |
| Gross profit | −$22,918 | −$28,855 | $2,006 | −$31,059 | −$30,742 | $1,800 | $1,800 | −$29,271 | $4,800 | −$29,271 | −$23,721 | $3,600 |
| Research & development | $459,200 | $541,658 | $550,077 | $465,154 | $501,260 | $743,304 | $471,840 | $581,796 | $924,749 | $422,392 | $349,408 | $992,722 |
| Sales, general & admin | $1.1M | $888,640 | $1.4M | $776,821 | $731,517 | $888,397 | $1.4M | $498,607 | $676,086 | $671,484 | $1.4M | $531,042 |
| Total operating expenses | $1.5M | $1.5M | $1.9M | $1.2M | $1.2M | $1.7M | $1.9M | $1.1M | $1.6M | $1.1M | $1.7M | $1.5M |
| Operating income | −$1.6M | −$1.5M | −$1.9M | −$1.3M | −$1.3M | −$1.7M | −$1.9M | −$1.1M | −$1.6M | −$1.1M | −$1.8M | −$1.5M |
| Interest income | $50,913 | $55,436 | $58,108 | $37,100 | $30,217 | $22,381 | $31,660 | $69,539 | $67,578 | $81,603 | $93,265 | $89,233 |
| Interest expense | — | — | — | — | — | — | — | — | — | $50 | $50 | — |
| Income before taxes | −$1.5M | −$1.4M | −$1.9M | −$1.2M | −$1.2M | −$1.6M | −$1.9M | −$1.0M | −$1.6M | −$1.0M | −$1.7M | −$1.5M |
| Income taxes | $726 | $1,360 | — | — | — | — | — | −$1.0M | −$1 | −$1 | −$1 | −$23,021 |
| Net income | −$1.5M | −$1.4M | −$1.9M | −$1.2M | −$1.2M | −$1.6M | −$1.9M | −$1.0M | −$1.6M | −$1.0M | −$1.7M | −$1.5M |
| EBITDA | −$1.5M | −$1.4M | −$1.9M | −$1.2M | −$1.2M | −$1.6M | −$1.9M | −$1.0M | −$1.5M | −$1.0M | −$1.7M | −$1.4M |
| EPS (diluted) | −$0.41 | −$0.38 | −$0.80 | −$0.48 | −$0.48 | −$0.83 | −$1.12 | −$0.75 | −$1.11 | −$0.73 | −$1.19 | −$1.02 |
| Gross margin | — | — | 66.9% | — | — | 60.0% | 60.0% | — | 60.0% | −975.7% | −790.7% | 60.0% |
| Operating margin | — | — | −64,859.4% | — | — | −55,349.3% | −62,857.8% | — | −20,316.3% | −37,438.2% | −59,061.3% | −25,719.8% |
| Net margin | — | — | −62,922.5% | — | — | −54,603.2% | −61,802.5% | — | −19,471.6% | −34,718.1% | −55,952.5% | −24,232.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CELZ's financial statements (latest annual report filed March 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CELZ financial results
In fiscal year 2025 (ended December 31, 2025), Creative Medical Technology reported revenue of $0.0 million, down 45.5% from the year before. It had a net loss of $6.0 million, a net profit margin of −99,916.8%. Diluted earnings per share came to −$2.59. Over five years revenue grew at an average rate of −48.4% a year.
See the CELZ stock overview for the latest quote and news, or the CELZ chart for price history and technical indicators.
CELZ income statement FAQ
What is Creative Medical Technology's annual revenue?
Creative Medical Technology reported total revenue of $0.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 45.5% from $0.0 million the previous year.
Is Creative Medical Technology profitable?
No. Creative Medical Technology reported a net loss of $6.0 million in fiscal 2025, a net profit margin of −99,916.8%; its operating margin was −102,380.2%.
What is Creative Medical Technology's gross margin?
Creative Medical Technology's gross margin was 63.4% in fiscal 2025: for every $100 of revenue, Creative Medical Technology kept $63 after the direct cost of its products and services.
How much does Creative Medical Technology spend on research and development?
Creative Medical Technology spent $2.3 million on research and development in fiscal 2025, 37,663.3% of revenue.
How fast is Creative Medical Technology growing?
Revenue grew −48.4% a year on average over the last five fiscal years, from $0.2 million to $0.0 million.
What are Creative Medical Technology's earnings per share?
Creative Medical Technology earned $-2.59 per diluted share in fiscal 2025, compared with $-3.71 a year earlier.
When will Creative Medical Technology report its next earnings?
Creative Medical Technology is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does Creative Medical Technology's fiscal year end?
Creative Medical Technology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 20, 2026.